Scientific and medical news

?-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction

25.11.20141571

The long-term efficacy of ?-blockers in patients with and without myocardial infarction (MI) is controversial.

Patients with treatment-resistant arterial hypertension had significant reductions in office-measured and ambulatory BP following arteriovenous anastomosis with a mechanical device, according to results from the CONTROL-HTN study presented at VIVA 14

21.11.20140

Researchers for the prospective, controlled, blinded, multicenter study evaluated 83 patients with treatment-resistant hypertension.

Association of Inpatient vs. Outpatient Onset of ST-Elevation Myocardial Infarction With Treatment and Clinical Outcomes

20.11.20141654

What are the incidence and variables associated with treatment and outcomes of patients with inpatient-onset ST-segment elevation myocardial infarction (STEMI)?

What is the Long-Term Cause of Death in STEMI Patients Treated With Primary PCI?

19.11.20141832

The risk of cardiac mortality declines to less than 1.5 percent per year following survival after a ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), and noncardiac causes are responsible for the majority of later deaths in these patients, according to a study published Nov. 10 in the Journal of the American College of Cardiology.

The QT Interval Is Associated With Incident Cardiovascular Events: The MESA Study

18.11.20142081

Study Question: Is the baseline QT interval predictive of negative cardiovascular outcomes?

Study Examines Follow-Ups in Adolescents With Family History of Brugada Syndrome

17.11.20141531

В соответствии с исследованием, опубликованным 16 ноября в журнале Американской медицинской ассоциации, у пациентов с семейным анамнезом синдрома Бругада и отрицательным результатом теста, проведенным в детстве, синдром может развиться в последующей жизни в результате действия гормональных, вегетативных или генетических факторов.

Clinical trial will explore bone marrow-derived cell therapy for HF

14.11.20141575

The FDA has accepted an application to begin a phase 3 clinical trial of bone marrow-derived cell therapy for patients with HF, according to a press release from BioCardia Inc.